米氮平治疗伴有睡眠障碍的围绝经期综合征的临床疗效分析
Mirtazapine in the treatment of perimenopausal syndrome with sleep disorders
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2021, 48(1) |
| 作者 |
|
| 作者单位 |
平煤神马医疗集团总医院 妇科 ;
|
| 摘要 |
目的：分析伴有睡眠障碍的围绝经期综合征行米氮平治疗的临床疗效。方法：本次时间选取2017年1月-2019年5月内，对象选取伴有睡眠障碍的围绝经期综合征患者60例，均根据随机法分组，2组各30例。采用谷维素片治疗控制组，采用米氮平治疗实验组。比较两个组别治疗前、后4w、8w时HAMD、PSQI等评分变化、总体疗效及不良反应。结果：两个组别治疗后4w、8w时HAMD、PSQI等评分对比发现实验组更优，P<0.05，说明差异显著；而二者治疗前对比未表现出明显差异（P>0.05）。两个组别治疗总有效率对比发现实验组更优，P<0.05，说明差异显著。两个组别不良反应率对比发现控制组更优，P<0.05，说明差异显著。结论：伴有睡眠障碍的围绝经期综合征行米氮平治疗效果较为确切，可对患者睡眠质量和抑郁症状予以显著改善，但不良反应相对较多，因此还需进一步增加用药时间观察。
|
| Abstract |
Objective: to analyze the clinical effect of mirtazapine on perimenopausal syndrome with sleep disorder. Methods: from January 2017 to may 2019, 60 patients with perimenopausal syndrome with sleep disorders were selected and randomly divided into two groups, 30 in each group. The control group was treated with oryzanol tablets and the experimental group was treated with mirtazapine. The changes of HAMD and PSQI scores, the overall efficacy and adverse reactions were compared between the two groups before, 4 and 8 weeks after treatment. Results: the scores of HAMD and PSQI in the two groups were better than those in the experimental group (P < 0.05). The total effective rate of the two groups was better than that of the experimental group (P < 0.05). The adverse reaction rate of the two groups was better than that of the control group (P < 0.05). Conclusion: the effect of mirtazapine in the treatment of perimenopausal syndrome with sleep disorders is more accurate, which can significantly improve the sleep quality and depression of patients, but there are relatively more adverse reactions, so it is necessary to further increase the observation of medication time.
|
| 关键词 |
围绝经期综合征；睡眠障碍；米氮平；临床疗效
|
| KeyWord |
perimenopausal syndrome; sleep disorders; mirtazapine; clinical efficacy
|
| 基金项目 |
|
| 页码 |
108-110 |
李慧丽*.
米氮平治疗伴有睡眠障碍的围绝经期综合征的临床疗效分析 [J].
国际精神病学杂志.
2021; 48; (1).
108 - 110.